A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 25
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : FDC
Long Form : full donor chimerism
No. Year Title Co-occurring Abbreviation
2020 Co-infusion of high-dose haploidentical donor cells and CD19-targeted CART cells achieves complete remission, successful donor engraftment and significant CART amplification in advanced ALL. B-ALL, CD19-CART, gDNA, GVHD
2020 Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI). CI, GVHD, pDLI
2019 Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms. allo-HCT, CI, CIK, TLI-ATG
2018 Early achievement of full donor chimerism after allogeneic hematopoietic stem cell transplantation predicts lower relapse risk in patients with acute lymphoblastic leukemia. ALL, HSCT, OS, RFS, STR
2018 [Prognostic significance of early phase donor chimerism after allogeneic peripheral blood stem cell transplantation]. aGVHD, allo-PBSCT, cGVHD, DC, DFS, OS, PCR-STR, RR
2017 Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained. DLI, GVM, HSCT, MC, OS, PFS, RR
2015 Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies. CI, DLI, EFS, FWI, GVHD, IT, MC
2011 Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. MSD, SAA, UD
2011 WT1-specific CTL cells of recipient origin may exist in the peripheral blood of patients achieving full donor chimerism soon after nonmyeloablative transplantation. LAA, NST
10  2009 [Multicenter report of nonmyeloablative allogeneic stem cell transplantation for hematologic diseases]. ATG, BU, CsA, Flud, GVHD, MC, MMF, NST
11  2008 Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCT. GVT, HSCT
12  2008 [Acute graft versus host disease in non-myeloablative allogeneic stem cell transplantation]. aGVHD, MC, NAST
13  2007 Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. GVHD, MC, pDLI
14  2007 The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants. DLI, MC, RIC
15  2006 Nonmyeloablative allogeneic hematopoietic stem cell transplantation in 26 cases of hematological malignancies. allo-NST, CsA, DLI, DSI, MTX, STRs
16  2006 [Quantitative analysis of donor chimerism in adoptive immunotherapy following allogeneic hematopoietic stem cell transplantation]. allo-HSCT, DC, DLI, GVHD, MC
17  2005 Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting. ---
18  2005 Evaluation of mixed chimerism in bone marrow transplantation program in Croatia. BMT, MC, PCR, STR
19  2005 Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens. EFS, MC, OS, PMC, RMC, SMC
20  2005 [Establishment of rhesus model for haploidentical hematopoietic stem cell transplantation with nonmyeloablative conditioning]. ---
21  2005 [First report on assessment of the status of engraftment after allogeneic hematopoietic stem cell transplantation by using denaturing high-performance liquid chromatography]. allo-HSCT, DHPLC, STR
22  2004 [Non-myeloablative allogeneic stem cell transplantation in patients with hematologic malignancies]. allo-NST, CsA, DLI, DSI, MTX, STRs
23  2004 [Sequential and quantitative analysis of chimerism after non-myeloablative stem cell transplantation]. CML, DC, GVHD, MC, NST
24  2003 Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. BMT, GVHD, MC, pDLI
25  2003 [Clinical significance of formation and conversion of hematopoietic mixed chimerism in nonmyeloablative allogeneic stem cell transplantation]. aGVHD, cGVHD, GVHD, MC, NAST, NAST